Low-Dose Parenteral @entity1460 Oil for the Prevention of Parenteral Nutrition-Associated XXXX in Neonates With @entity344 : A Multicenter Randomized Controlled Pilot Study.

@entity1 @entity295 @entity6841 @entity648 @entity409 @entity344 @entity1448 @entity1460
BACKGROUND: Neonates with @entity344 ( @entity344 ) are at high risk for @entity409 ( @entity409 ). @entity1460 -based intravenous lipid emulsions (S-ILE) have been associated with @entity409 . This study's objective was to determine if a lower dose compared with a higher dose of S-ILE prevents @entity1448 without compromising growth. MATERIALS AND METHODS: This multicenter randomized controlled pilot study enrolled @entity1 with @entity344 who were  <=5 days of age to a low dose (~1 g/kg/d) (LOW) or control dose of S-ILE (~3 g/kg/d) (CON). The primary outcome was @entity1448 (direct @entity648 [DB] >2 mg/dL) after the first 7 days of age. Secondary outcomes included growth, @entity6841 duration, and late-onset @entity295 . RESULTS: Baseline characteristics were similar between the LOW (n = 20) and CON groups (n = 16). When the LOW group was compared with the CON group, there was no difference in @entity1448 (30% vs 38%, P = .7) or secondary outcomes. However, mean    SE DB rate of change over the first 8 weeks (0.07    0.04 vs 0.3    0.09 mg/dL/wk, P = .01) and entire study (0.008    0.03 vs 0.2    0.07 mg/dL/wk, P = .02) was lower in the LOW group compared with the CON group. CONCLUSION: In neonates with @entity344 who received a lower dose of S-ILE, DB increased at a slower rate in comparison to neonates who received a higher dose of S-ILE. Growth was comparable between the groups. This study demonstrates a need for a larger, randomized controlled trial comparing 2 different S-ILE doses for @entity1448 prevention in neonates at risk for @entity409 .
